s three principal business sectors: Therapeutics, Life Science Tools & Diagnostics, and BioEnergy/Cleantech. During the past two decades Flagship's principals have been involved as founders or investors in many highly successful ventures including: Adnexus Therapeutics, Alere Medical, Aspect Medical, Celera Genomics, ChemGenics Pharmaceuticals, Color Kinetics, Cytyc, Helicos Biosciences, Hypnion, IDEXX, Morphotek, PerSeptive Biosystems and TripAdvisor. For more information, please visit www.flagshipventures.com
About Baird Venture Partners
Baird Venture Partners, the U.S.-based venture capital fund of Baird Private Equity, makes venture capital investments in early and expansion stage business services and life sciences companies. Baird Venture Partners leverages its in-depth sector knowledge, experienced investment team and network of relationships to serve as a value-added partner for its portfolio companies. For more information, please visit www.bairdventurepartners.com.
About Arboretum Ventures
Arboretum Ventures is an early-stage venture capital firm specializing in the healthcare sector. Arboretum Ventures focuses primarily on investments in medical technology and healthcare services. Arboretum invests throughout the United States, with a special interest in the Midwest region. Founded in 2002 with headquarters in Ann Arbor, Mich., Arboretum Ventures currently manages $97 million in capital. For more information, please visit www.arboretumvc.com.
Accuri Cytometers Media
Jennifer A. Baird GendeLLindheim BioCom Partners
Chief Executive Officer Jennifer Anderson
Page: 1 2 3 4 5 Related biology technology :1
|SOURCE Accuri Cytometers, Inc.|
Copyright©2009 PR Newswire.
All rights reserved
. Accuri Cytometers Completes $13 Million Series C Financing2
. Accuri Cytometers Adds Automation to Its Revolutionary C6 Flow Cytometer(R) System With Commercial Launch of CSampler(TM)3
. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility4
. AEterna Zentaris completes management team with the appointment of Chief Medical Officer5
. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML6
. Carrington Completes $8 Million Financing7
. Proteon Therapeutics Completes $12 Million Financing and Hires CFO8
. New Brunswick Scientific Completes Merger Transaction with Eppendorf9
. Kiwa Bio-Tech Completes 1st Stage of Shandong Factory Upgrading10
. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.11
. Optherion, Inc. Completes $37 Million Start Up Financing